<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4033">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335162</url>
  </required_header>
  <id_info>
    <org_study_id>20reamedcovid01</org_study_id>
    <nct_id>NCT04335162</nct_id>
  </id_info>
  <brief_title>Cardiovascular Complications and COVID-19 (CovCardioVasc-Study)</brief_title>
  <acronym>CovCardioVasc</acronym>
  <official_title>Cardiovascular Complications in Patients With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have&#xD;
      a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk&#xD;
      profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be&#xD;
      elevated in a high proportion of patients (one fifth of all patients and 50% of&#xD;
      non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of&#xD;
      non survivors) and fibrin degradation products are also associated with increased risk of&#xD;
      mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for&#xD;
      cardiomyopathies and venous thromboembolism could represent an important challenge for&#xD;
      patients with COVID-19 management.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2020</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the incidence of cardiomyopathies and venous thromboembolism</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of cardiomyopathies and/or venous thromboembolism at day 28</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence of mortality at day 28</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of mechanical ventilation</measure>
    <time_frame>hospitalisation duration</time_frame>
    <description>Number of day of using mechanical ventilation for each patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Shock</measure>
    <time_frame>hospitalisation duration</time_frame>
    <description>Incidence of shock during hospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of stay</measure>
    <time_frame>hospitalisation duration</time_frame>
    <description>Number of day at hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mechanical ventilation</measure>
    <time_frame>hospitalisation duration</time_frame>
    <description>Setting up or not of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal replacement therapy</measure>
    <time_frame>hospitalisation duration</time_frame>
    <description>Administration or not of renal replacement therapy</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>COVID</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Myocardial Infarction</condition>
  <condition>Myocarditis</condition>
  <condition>Venous Thromboembolism</condition>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Patients with cardiovascular complications</arm_group_label>
    <description>Patients presenting with cardiomyopathies or venous thromboembolism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients without cardiovascular complications</arm_group_label>
    <description>Patients without cardiomyopathies or venous thromboembolism</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intensive Care Unit patients</arm_group_label>
    <description>Patients admitted in intensive care unit</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hospital Ward patients</arm_group_label>
    <description>Patients admitted in hospital ward</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Intensive care unit, hospital ward&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - All consecutive patients with COVID-19 infection admitted to the ICU or hospitalized&#xD;
        because of severe form (eg: hypoxia, orthopnea, pneumonitis, kidney insufficiency) will be&#xD;
        included&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Patients under 18 years&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Denis DOYEN</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de NICE - Archet 1</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denis DOYEN</last_name>
    <phone>0033492035510</phone>
    <email>doyen.d@chu-nice.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier de Cannes</name>
      <address>
        <city>Cannes</city>
        <zip>06400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Marie BERTRAND</last_name>
      <email>PM.BERTRAND@ch-cannes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexandre ROBERT</last_name>
      <email>A.ROBERT@ch-cannes.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Belaid BOUHEMAD</last_name>
      <email>belaid_bouhemad@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Draguignan</name>
      <address>
        <city>Draguignan</city>
        <zip>83300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andres Jurado</last_name>
      <email>andres.jurado@wanadoo.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Grasse</name>
      <address>
        <city>Grasse</city>
        <zip>06130</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre-Marie Bertrand</last_name>
      <email>pm.bertrand@ch-cannes.fr</email>
    </contact>
    <contact_backup>
      <last_name>Alexandre Robert</last_name>
      <email>a.robert@ch-cannes.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Clinique Ambroise-Paré</name>
      <address>
        <city>Neuilly</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lee NGUYEN</last_name>
      <email>nguyen.lee@icloud.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis DOYEN</last_name>
      <phone>0033492035510,</phone>
      <email>doyen.d@chu-nice.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Universitaires Paris Centre - Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mathieu Jozwiak</last_name>
      <phone>0033158412661</phone>
      <email>mathieu.jozwiak@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Jonathan MAREY</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de REIMS</name>
      <address>
        <city>Reims</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent DUPONT</last_name>
      <email>vdupont@chu-reims.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Thromboembolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thromboembolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Myocarditis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>no data sharing plan has been established.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

